Tag Archives: New York Times

WSJ: A Piece of the Immunotherapy Puzzle Solved

Just two weeks ago, the New York Times published a series of articles deeming immunotherapy as the future for cancer advances and new life-saving treatments – even though it’s not entirely clear why only some patients have success with the treatments. This week, the Wall Street Journal joined the immunotherapy conversation by highlighting two researchers who may have unlocked part of the mystery as to why only some patients benefit from immunotherapy. When Dr. Michael Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

ICYMI: NYT Chronicles Advances in Cancer Landscape Due to Immunotherapy

health care, medicine

This week, the New York Times published a series of articles titled Cell Wars which explores the novel uses of immunotherapy to combat cancer. Patient stories were shared where immunotherapy cured them of lung, prostate, liver, and brain cancer. Included were stories of researchers who have dedicated their lives to finding new treatments and cures. As the article states, there is a new era of optimism — a sense that they have begun tapping into a force of Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

FOIA Attacks Against Biotech Scientists Get Personal

Alison Van Eenennaam

Much has been written and discussed online about the relationships between independent researchers and industry groups.  New York Times reporter Eric Lipton wrote about this in a detailed September 5 article, “Food Industry Enlisted Academics in GMO Lobbying War, Emails Show”. Lipton’s article comes about 6 months after U.S. Right to Know (USRTK) filed FOIA requests for emails and documents of more than forty public university faculty and staff members seeking to link these individuals Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Ezekiel Emanuel’s Flawed Solution

Jim Greenwood

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug Prices.” The piece is problematic in many respects, but we agree with one of his primary contentions: in discussions about drug prices, value is the real issue. This point was nicely made in a recent Times piece, where it quoted Crystal Bedford, whose five year old daughter, Marley, suffers from a rare genetic disease, Rhizomelic Chondrodysplasia Punctata (RCPD). A treatment Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Jim Greenwood in New York Times: Specialty Tiers Limit Patient Access

Jim Greenwood

Today, the New York Times published a letter from Jim Greenwood, BIO’s President and CEO. Greenwood’s letter discusses the problems that expanded use of specialty tier cost-sharing by the insurance industry are posing for patients, limiting their access to lifesaving therapies and cures. Breakthrough treatments cost billions of dollars, and investors will only take on such risks if they can expect a reasonable return on their investment. The full text of the letter is below: To Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,